Phase Ib/II trial of talimogene laherparepvec alone and with pembrolizumab in advanced solid tumors with liver metastases and hepatocellular carcinoma

By sjmartinez • March 30, 2025

Hecht JR, Oberoi A, Garralda Cabanas E, Jae Chon H, Digklia A, Rottey S, Martin Jimenez M, Chaney M, Hippenmeyer J, Lawrence T, Liu K, Hamidi A, Chesney J. Phase Ib/II trial of talimogene laherparepvec alone and with pembrolizumab in advanced solid tumors with liver metastases and hepatocellular carcinoma. Oncologist. 2025 Mar 10;30(3):oyae203. doi: 10.1093/oncolo/oyae203. PMID: 40156118.

Tags: Hematology/Oncology, Hepatocellular carcinoma, liver metastasis, pembrolizumab, Publications, Solid tumor, talimogene laherparepvec

Impact of postoperative FDG-PET/CT on adjuvant head and neck cancer treatment

Courtney PT, Juarez Casillas JE, Liu EY, Sim MS, Chau LW, Lopez-Chicas RE, St John MA, Abemayor E, Blackwell KE, Chhetri DK, Gopen QS, Kedeshian[...]

Datopotamab Deruxtecan-Associated Select Adverse Events: Clinical Practices and Institutional Protocols on Prophylaxis, Monitoring, and Management

Lisberg A, Huppert LA, Halmos B, Ledezma B, Soto-Romano V, Traina TA. Datopotamab Deruxtecan-Associated Select Adverse Events: Clinical Practices and Institutional Protocols on Prophylaxis, Monitoring,[...]

Imaging Interoperability: #DitchtheDisk is a Health Equity Imperative for Lung Cancer Screening & Beyond

Tupper HI, Mendelson DS, Doo FX, Carlos RC, Bialecki B, Prosper AE, Moghanaki D, Servais EL, Flores EJ, Cummings AL. Imaging Interoperability: #DitchtheDisk is a[...]